Efficacy and safety of tocilizumab and baricitinib among patients hospitalized for COVID-19: a systematic review and meta-analysis
J Zhang, X Fan, X Zhang, F Jiang, Y Wu… - Frontiers in …, 2023 - frontiersin.org
Introduction: Tocilizumab and baricitinib are recommended treatment options for COVID-19
patients with hyperinflammatory response; however, there is a lack of systematic review …
patients with hyperinflammatory response; however, there is a lack of systematic review …
HIV and COVID-19 co-infection: epidemiology, clinical characteristics, and treatment
D Basoulis, E Mastrogianni, PM Voutsinas… - Viruses, 2023 - mdpi.com
The COVID-19 pandemic has been a global medical emergency with a significant socio-
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
economic impact. People with HIV (PWH), due to the underlying immunosuppression and …
COVID-19 biomarkers at the crossroad between patient stratification and targeted therapy: the role of validated and proposed parameters
M Rizzi, D D'Onghia, S Tonello, R Minisini… - International Journal of …, 2023 - mdpi.com
Clinical knowledge about SARS-CoV-2 infection mechanisms and COVID-19
pathophysiology have enormously increased during the pandemic. Nevertheless, because …
pathophysiology have enormously increased during the pandemic. Nevertheless, because …
Efficacy and safety of novel oral antivirals in hospitalized COVID-19 patients: A network meta-analysis of randomized clinical trials
H Liu, J Chen, W Shao, S Yan, S Ding - Clinical Epidemiology, 2023 - Taylor & Francis
Objective Numerous pharmacological interventions are now under investigation for the
treatment of the 2019 coronavirus pandemic (COVID-19), and the evidence is rapidly …
treatment of the 2019 coronavirus pandemic (COVID-19), and the evidence is rapidly …
The efficacy and safety of complement C5a inhibitors for patients with severe COVID-19: a systematic review and meta-analysis
CL Tsai, CC Lai, CY Chen, HS Lee - Expert Review of Anti-infective …, 2023 - Taylor & Francis
Background The clinical efficacy and safety of complement C5a inhibitors for patients with
severe COVID-19 remains unclear. Methods The PubMed, Embase, Cochrane Library, and …
severe COVID-19 remains unclear. Methods The PubMed, Embase, Cochrane Library, and …
Efficacy and safety of baricitinib in patients with severe COVID-19: A systematic review and meta-analysis
W Song, S Sun, Y Feng, L Liu, T Gao, S Xian, J Chen - Medicine, 2023 - journals.lww.com
Background: This study aimed to investigate the efficacy and safety of baricitinib in patients
with severe coronavirus disease 2019 (COVID-19). Methods: Databases were searched for …
with severe coronavirus disease 2019 (COVID-19). Methods: Databases were searched for …
Comparison of Tocilizumab vs Baricitinib in Clinical Outcomes Among Hospitalized Patients With COVID-19: Experience From a Public Hospital System in New York …
S Sunny, A Tran, J Lee, M Abdallah… - Open Forum …, 2023 - academic.oup.com
Background Tocilizumab and baricitinib are immunomodulators that have been repurposed
for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should …
for the treatment of coronavirus disease 2019 (COVID-19). Whether one medication should …
Care Bundles to Improve Hemoperfusion Performance in Patients with Severe COVID-19: A Retrospective Study
S Mueankwan, K Trongtrakul, P Tajarernmuang… - Journal of Clinical …, 2024 - mdpi.com
Background/Objectives: Hemoperfusion (HP) is employed to modulate cytokine storms in
severe coronavirus disease 2019 (COVID-19) patients, requiring careful attention for …
severe coronavirus disease 2019 (COVID-19) patients, requiring careful attention for …
[HTML][HTML] SARS-CoV-2 Infection-Induced Necrotising Sarcoid Granulomatosis
SARS-CoV-2 infection is a pandemic that affects predominantly upper airways and lungs. It
may lead to reactivation of known inflammatory rheumatic diseases and/or initiation of …
may lead to reactivation of known inflammatory rheumatic diseases and/or initiation of …
[PDF][PDF] OF RHEUMATOLOGY
AS Koc¹, N Fener, S Kobak - 2023 - mjrheum.org
ABSTRACT SARS-CoV-2 infection is a pandemic that affects predominantly upper airways
and lungs. It may lead to reactivation of known inflammatory rheumatic diseases and/or …
and lungs. It may lead to reactivation of known inflammatory rheumatic diseases and/or …